To include your compound in the COVID-19 Resource Center, submit it here.

Amevive: Phase II data; Phase III

BGEN said data from an ongoing Phase II trial showed 174 patients retreated

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE